Jehad Jafari, MD
Hospitalist · Jefferson City, MONPI 1356396634
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $665 and has fallen 90.4% since, to $64 in 2021. Among hospitalist clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $14.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$197
- Amarin Pharma, Inc.$147
- Novartis$122
- Amgen$106
- Corcept Therapeutics$85
- Astellas Pharma US Inc$65
- plus $439 from 13 others
What the payments were for
- Food & beverage$1,161100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $197 |
| Amarin Pharma, Inc. | 8 | $147 |
| Novartis | 8 | $122 |
| Amgen | 6 | $106 |
| Corcept Therapeutics | 5 | $85 |
| Astellas Pharma US Inc | 4 | $65 |
| Boehringer Ingelheim | 3 | $63 |
| Arbor Pharmaceuticals, Inc. | 4 | $60 |
| Kowa Pharmaceuticals America, Inc. | 4 | $52 |
| AstraZeneca | 4 | $50 |
| Johnson & Johnson | 4 | $48 |
| Merck | 2 | $27 |
| Esperion Therapeutics, Inc. | 1 | $26 |
| Lilly USA, LLC | 2 | $25 |
| AbbVie | 1 | $25 |
| Circassia Inc. | 1 | $18 |
| Bioventus LLC | 1 | $17 |
| GSK | 1 | $14 |
| Dexcom, Inc. | 1 | $12 |
How this compares
$1,161 in reported general payments places this provider in the 90th percentile of 712 hospitalist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CefuroximeCefuroxime Axetil | 14 | $95 |
| Metoprolol Tartrate | 11 | $22 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Jefferson City
- Harjeet SinghJefferson City$714
- Mir ZulqarnainKansas City$161K
- Gian MusarraSaint Louis$25K
- Ghassan DaherSaint Louis$23K
- Marsha SchulteSaint Louis$23K
- Ijeoma NwelueSaint Louis$12K
- Karan MohanSt. Joseph$6K
- Aniesh BobbaColumbia$6K
- Arun MannemSaint Louis$6K
- Vasanthan KuppuswamySaint Louis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.